RISE CAB training package
Skip to content

Long-acting injectable cabotegravir (CAB) for PrEP was approved by US FDA in December 2021, and the medication has been endorsed in several guidelines. It’s considered a game changer for providers and organizations to serve certain populations in need of HIV prevention for which daily oral PrEP has been suboptimal. However, the number of current CAB for PrEP clients within health centers that already provide oral PrEP services in the USA has been relatively low nationwide.

Read the full story here on the Science Speaks blog, from the Infectious Diseases Society of America, to learn why insurance company responses to CAB for PrEP prescriptions may be contributing to low uptake of CAB for PrEP in the USA.